Asthma‐related mortality ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related mortality ‐ adults and adolescents compared with regular salbutamol (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ adults and… compared with regular salbutamol (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with regular salbutamol (low certainty).
1 finding from 1 review
All‐cause mortality ‐ children · patients with chronic asthma
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol leads to higher all‐cause non‐fatal serious adverse events ‐ adults and adolescents compared with placebo (high certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
1 finding from 1 review
Asthma‐related mortality ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol leads to higher asthma‐related mortality ‐ adults and adolescents compared with placebo (high certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ adults and… compared with placebo (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause mortality ‐ adults and adolescents compared with regular salbutamol (moderate certainty).
1 finding from 1 review
All‐cause mortality ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause mortality ‐ children compared with regular salbutamol (low certainty).
1 finding from 1 review
Intervention not reported
Hospital admission/re‐admission · Adults who attend the emergency room for acute asthma
The intervention leads to lower hospital admission/re‐admission (high certainty).
1 finding from 1 review
Intervention not reported
Presentation at emergency department · Adults who attend the emergency room for acute asthma
The intervention showed no clear difference in presentation at emergency department (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life (SGRQ) ‐ Total scores SGRQ units. Scale from: 0 to 100. · Adults who attend the emergency room for acute asthma
1 finding from 1 review